Clinical Trial Update: U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne [Phase 4]

View source ↗

Summary

Phase 4 open-label trial evaluating MAXCLARITY II for acne vulgaris completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• MAXCLARITY II

Snippet

Sponsor: Stiefel, a GSK Company | Conditions: Acne Vulgaris | Phase 4 | Status: COMPLETED | Results posted: 2018-01-08